PepGen(PEPG) - 2025 Q2 - Quarterly Results

PepGen Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights – Last patient dosed in 15 mg/kg cohort of FREEDOM-DM1; on track to report topline data from study in early Q4 2025 – – FREEDOM to conclude with the 15 mg/kg cohort based on splicing and safety data observed to date; clinical sites will begin transitioning to the Phase 2 multiple ascending dose study, FREEDOM2-DM1 – BOSTON— August 7, 2025-- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the nex ...